

HEALTHCARE SECTOR BULLETIN

October 2015

QUADRIA
CAPITAL

HEALTHCARE TRENDS & IMPACT STORIES

Country: Vietnam

Headline: **Private investment eyeing healthcare**

Summary: Analysts said that many of the Government's recently issued policies had encouraged private investors to participate in medical care projects. Public medical establishments are allowed to enter into a joint venture with private investors to set up new medical examination and treatment facilities that will operate under the Enterprise Law.

Nguyen Nam Lien, director of the Ministry of Health's Financial Planning Department, said in an interview with Tuoi Tre (Youth) newspaper that Viet Nam's demand for investment in hospitals was still huge. "The World Health Organisation recommended a ratio of 39 beds to 10,000 people while this ratio in Viet Nam was 24/10,000. To reach WHO's ratio, the country would have to build 60 more hospitals with a capacity of 1,000 beds," Lien said. "The health sector's investment demand cannot be met by the Government, so it is necessary to mobilise capital from various resources," he said.

"Hospitals would be able to borrow capital from banks or participate in PPP. The investors, for instance, could inject their capital into building infrastructure and buying medical instruments, and the hospitals would then lease them," he said.

Link <http://vietnamnews.vn/economy/277567/private-investment-eyeing-healthcare.html>

Country: India

Headline: **Pharma companies team up to clean industry's image**

Summary: Some of India's biggest pharmaceutical companies, cutting across their respective associations and representing nearly half the Rs 93,000 crore market, have come together to push for ethical marketing practices to clean up the industry's image.

The forum, comprising of 40 to 50 domestic and MNC firms, had its first closed-door meeting on October 14. It has made a "voluntary and moral commitment" to follow ethical marketing practices in "letter and spirit", and will work with the regulatory mechanism to facilitate the exercise.

This comes even as the government has already expressed its intention to make the 'Uniform Code of Pharmaceutical Marketing Practices' mandatory from next year. The code — banning cruise tickets, freebies and paid vacations for doctors sponsored by drug companies — is voluntary at present. But in light of rampant violations, the government plans to make it binding on companies.

The group — which includes top MNCs like Novartis, MSD and Abbott, and domestic firms Sun Pharma, Zydus Cadila and Dr Reddy's among others — wants to start a movement and build pressure on those who are not following ethical practices. A "voluntary" coming together out of sheer "moral commitment carries greater weightage" than guidelines being thrust on them, said an expert, who is part of the forum. "We have come together voluntarily to push for ethical marketing practices," IPA director general D G Shah said. "Over the years, our industry has been maligned."

Link <http://timesofindia.indiatimes.com/india/Pharma-companies-team-up-to-clean-industrys-image/articleshow/49445774.cms>

HEALTHCARE SECTOR NOTABLE TRANSACTIONS

Country: Malaysia

Headline: **Singapore ISEC Healthcare buys Malaysia's eye specialist clinic SSEC for USD 8.79m**

Summary: ISEC Healthcare, via its subsidiary ISEC Sdn Bhd, has agreed to acquire the entire issued and paid-up share capital of Malaysia-based Southern Specialist Eye Centre Sdn Bhd (SSEC) for MYR 37.1m (USD 8.79m). The consideration is about 12.43x of the unaudited adjusted and normalised profit after tax of the clinic for financial year 2014 of MYR 2.98m.

ISEC saw the proposed acquisition as an opportunity to expand the group's eye specialist clinic footprint in Malacca, which serves as an established gateway to health tourists from Southern Sumatra and the Riau Bintang Islands. "It is also intended to tap into the affluent local market and also Singapore patients who may consider having their procedures to be performed in Malacca which is about three-hours drive away from Singapore," the Singapore-listed company added in its stock exchange filing.

ISEC also noted that as the principal business of SSEC is in line with the ordinary course of business of the group and there would be no additional borrowings to fund the proposed acquisition, the deal is not expected to have any material change to the group's risk profile.

SSEC, a private limited company incorporated in Malaysia, operates specialist eye clinics. The resident consultant ophthalmologists of SSEC's clinic in Malacca are Dr Yeo Kim Chuan, Dr Yang Phei Hua, Dr Wong Yew Meng and Dr Liu Han Seng. Yeo and his wife, Wong and Liu are the vendors of the shares.

Links: <http://www.dealstreetasia.com/stories/singapore-isec-healthcare-buys-malaysias-eye-specialist-clinic-ssec-for-8-79m-16173/>

Country: India

Headline: **Recipharm buys 74% stake of Indian CMO, Nitin Lifesciences**

Summary: Recipharm, a Sweden-based CDMO (Contract Development and Manufacturing Organisation) has announced an agreement to acquire 74% of Nitin Lifesciences Limited - a sterile injectables CMO headquartered at Karnal in Northern India - for an estimated cost of INR 6,712m (USD 103m).

"The growth in the domestic Indian Pharma market is tremendous and we wanted to find a way to participate in this," Executive Vice President Mark Quick said. "It is certainly true that there have been some quality issues in the region and we were of course aware of this before embarking on the project. We took this into account when we conducted our due diligence and looked very carefully at this."

The acquisition is the latest for Recipharm, and Quick said it forms part of an aggressive growth strategy being followed since the firm went public in June 2014. "It is very clear that our industry is undergoing a rapid structural change and we want to be one of the drivers of this," he said. "The rationale for our IPO last year was to provide resources to participate and be a leading consolidator in the CDMO industry and we intend to continue to deliver on this commitment to fill the gaps we have both from a technological and geographical perspective."

Links: <http://www.businesstoday.in/current/corporate/carlyle-group-buys-37percent-stake-in-metropolis-healthcare/story/223614.html>

TRANSACTION NEWS

Date	Headlines	Summary
31-Oct	U-Home Group Holdings in trading halt pending announcement relating to possible acquisition (Source: Stock Exchange Announcement (s))	U-Home Group Holdings (HKG: 2327) made the following announcement to the Hong Kong stock exchange on 30 October: At the request of U-Home Group Holding Limited (the “Company”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 1:00 p.m. on Friday, 30 October 2015 pending the release of an announcement relating to possible acquisition and investment which is inside information of the Company.
31-Oct	Starlake Bioscience ends proposed asset restructuring (Source: Stock Exchange Announcement (Translated))	Starlake Bioscience [Xing Hu Ke Ji; SH:600866], a Guangdong-based food company, announced in a stock exchange announcement dated 31 October that it has terminated a proposed assets restructuring and will not plan any other restructurings within six months.
30-Oct	MicrobioPharm Japan acquires Kiyosu Plant business from Astellas Pharma (Source: Company Press Release(s))	Astellas Pharma [TYO:4503], the Japan-based pharmaceutical company, announced on 30 October 2015 an agreement to sell its Kiyosu Plant business to unlisted Japan-based pharmaceutical company MicroBiopharm Japan. Tokyo, 30 October 2015 - Astellas Pharma (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas and MicroBiopharm Japan (Headquarters: Tokyo, President: Masanobu Suzuki, “MBJ”) have concluded an agreement.
30-Oct	Shanghai Yaogu Pharmaceutical 92.04% stake up for sale with asking price of CNY 328.532m (USD 51.79m) (Source: Chinese Equity Exchange Announcement)	A 92.04% stake in Shanghai Yaogu Pharmaceutical has been put up for sale from 29 October to 26 November, according to an announcement posted on the Shanghai United Assets and Equity Exchange. The asking price is CNY 328.532m (USD 51.79m), the announcement said.
30-Oct	Shasun Pharmaceuticals scheme of amalgamation with Strides Arcolab approved by FIPB (Source: Stock Exchange Announcement(s) (Edited))	India-based Strides Arcolab has informed the BSE that the Foreign Investment Promotion Board (FIPB), Government of India, in a press release dated 28 October approved the company proposal for issuing shares to non-resident equity shareholders under the Scheme of Amalgamation (of the India-based Shasun Pharmaceuticals (BOM:524552) with Strides Arcolab).
29-Oct	Cipla to sell 25% in Biomab Holding to Biomab Brilliant for USD 25.775m (Source: Company Press Release(s) (Edited))	Cipla (BOM:500087), the India-based pharmaceutical company, on 29 October 2015, announced that it has entered into a definitive agreement to sell its entire 25% stake in Biomab Holding Ltd, Hong Kong (“BHL”) to Biomab Brilliant, British Virgin Islands, which holds the remaining 75% stake in BHL, for a total consideration of USD 25.775m.
29-Oct	Synergia Life Sciences 30% stake may be acquired by India Life Sciences Fund for an estimated USD 6m – report (Source: VCCircle)	Synergia Life Sciences, the Mumbai, India-based pharma, is in deal talks with private equity (PE) fund India Life Sciences Fund II (ILSF II) for the PE to buy a 30% stake in Synergia Life Sciences for INR 400m (USD 6m), VCCircle reported without citing sources.
29-Oct	China Resources Double-crane Pharmaceutical to buy 60% stake	China Resources Double-crane Pharmaceutical [Hua Run Shuang He; SH:600062], a listed Beijing-based pharmaceutical company, said its board meeting held on 27

	<i>in Jinan Limin Pharmaceutical for CNY 713.4m (Source: Stock Exchange Announcement (Translated))</i>	<i>October approved to buy a 60% stake in Jinan Limin Pharmaceutical [Li Min Zhi Yao], a Shandong-based pharmaceutical company.</i>
29-Oct	<i>Sun Pharmaceutical Industries completes cash tender offer for InSite Vision (Source: Company Press Release(s) (Edited))</i>	<i>India-based Sun Pharmaceutical Industries (BOM:524715, Sun Pharma) announced on 28 October the successful completion of a cash tender offer by Thea Acquisition (“Thea”), an indirect wholly owned subsidiary of Sun Pharma, for all outstanding shares of common stock of InSite Vision (OTCBB:INSV, InSite).</i>
29-Oct	<i>EBOS Group considering several acquisition targets (Source: Radio New Zealand International)</i>	<i>EBOS Group [NZX.EBOS], the New Zealand-based healthcare and animal care products company, is considering several acquisition targets, reported Radio New Zealand. The report cited Mark Waller, the managing director of the company, who said that the company may announce a potential deal in late November if the purchase is finalized.</i>
28-Oct	<i>Max Healthcare inks deal to acquire 51% stake in Saket City Hospital from Smart Health City (Source: Company Press Release(s) (Edited))</i>	<i>The India-based Max Healthcare (MHC) on 28 October 2015 announced a partnership with Smart Group wherein MHC would acquire 51% stake in the Delhi-based Saket City Hospital (SCH) from Smart Health City, the Singapore based BK Modi Group (Smart Group) company which manages and operates SCH.</i>
28-Oct	<i>Abano Healthcare appoints Rachel Walsh as CFO; has acquisition and divestment experience (Source: Stock Exchange Announcement*)</i>	<i>Abano Healthcare Group (NZX: ABA) today announced the appointment of Rachel Walsh, Abano’s current Group Commercial Manager, as its new Chief Financial Officer. Rachel will commence as Chief Financial Officer next month, when the current CFO/COO, Richard Keys, takes up the role of Chief Executive Officer.</i>
28-Oct	<i>Shinva Medical Instrument share trading halt remains, planning to buy a Hunan-based hospital (Source: Stock Exchange Announcement (Translated))</i>	<i>Shinva Medical Instrument [Xin Hua Yi Liao; SHE: 600587], a China-based, listed medical device manufacturer and distributor, said tonight its share trading halt, starting on 8 October, will remain on 29 November. According to the company stock exchange announcement, it is planning a fundraising via a private placement of new shares.</i>
28-Oct	<i>Biosensors receives offer from CITIC Private Equity (Source: Stock Exchange Announcement(s) (Edited))</i>	<i>The Board of Directors (the “Board”) of Biosensors International Group, Ltd. (“Biosensors” or the “Company”) [SGX: B20] wishes to inform shareholders that the Company received an offer (the “Offer”) from CITIC Private Equity Funds Management Co., Ltd..</i>
28-Oct	<i>Shanghai Kinetic Medical to buy remainder of two medical devices companies (Source: Stock Exchange Announcement (Translated))</i>	<i>Shanghai Kinetic Medical [Kai Li Tai; SZ: 300326] said in a stock exchange announcement dated 24 September that it plans to buy the stakes that it does not already own in Essen Technology (Beijing) [Yi Sheng Ke Ji] and Jiangsu IDEAL Medical Science & Technology [Ai Di Er]. Shanghai Kinetic Medical is a listed medical equipment maker.</i>
27-Oct	<i>Blockade Medical closes financing round led by TitanMed, GP Healthcare; forms JV to enter China's market (Source: Company press release.)</i>	<i>Blockade Medical LLC, a privately held company focused on the development of catheter based therapeutic devices for the treatment of cerebral aneurysms and ischemic stroke, announced today the closing of a round of equity financing.</i>

27-Oct	Ladprao General Hospital seeks to form JV, invest in medical services business (translated) (Source: Thunhoon)	<i>Ladprao General Hospital (LPH), a Thailand-based hospital, plans to form a medical services joint venture or invest in other hospitals, Thunhoon reported. Citing CEO Ungkoon Chantavanit, the Thai-language report said the hospital is seeking opportunities to maximize its competitive advantage through making such investments.</i>
27-Oct	Nipro to sell 100% stake in Nipro Diagnostics to Sinocare for USD 272m (Source: Stock Exchange Announcement (Translated))	<i>Nipro [TYO:8086], the Japan-based medical equipment maker, announced today it will sell its entire 100% stake in Florida-based glucose management systems subsidiary Nipro Diagnostics to China-based Sinocare [San Nuo Sheng Wu, 300298.CHI].</i>
27-Oct	TalkMed forms new joint venture with StemCord (Source: Stock Exchange Announcement*)	<i>TalkMed (SGX: 5G3), the Singapore-based medical haematology and oncology company, has formed a new joint venture with StemCord, according to a stock exchange announcement. StemCord Private Limited, a FACT-NetCord accredited private autologous cord blood bank, together with Stem Med Private Limited, a new joint venture between public-listed TalkMed Group Limited.</i>
27-Oct	Hunan Jingfeng Pharmaceutical to form chemical medicine JV (Source: Stock Exchange Announcement (Translated))	<i>Hunan Jingfeng Pharmaceutical [Jing Feng Yi Yao; SZ: 000908], the Chinese listed entity, will set up a 51:49 joint venture with a group of U.S.-based research team to produce chemical medicine, according to a stock exchange announcement dated 27 October.</i>
27-Oct	Sichuan Languang Development ends proposed acquisition of Xi'an Xintong Pharmacy (Source: Stock Exchange Announcement (Translated))	<i>Sichuan Languang Development [Lan Guang Fa Zhan; SHA: 600466], a China-based property developer, has abandoned a proposed major asset restructuring which targeted Xi'an Xintong Pharmacy [Xin Tong Yao Wu Yan Jiu], a medicine R&D company.</i>
27-Oct	Tibet Rhodiola Pharmaceutical ends proposed major asset restructuring (Source: Stock Exchange Announcement (Translated))	<i>Tibet Rhodiola Pharmaceutical [Xi Zang Yao Ye; SH: 600211], a China-based listed company, said in a stock exchange announcement today that it has terminated a proposed major asset restructuring due to disagreement over pricing of its target.</i>
27-Oct	Shanghai Modern Pharmaceutical confirms major asset restructuring proposal (Source: Stock Exchange Announcement (Translated))	<i>Shanghai Modern Pharmaceutical [Xian Dai Zhi Yao; SH: 600420], a listed Chinese pharmaceutical company, confirmed in a stock exchange announcement on 27 October that it is planning a major asset restructuring. It was earlier reported that Shanghai Modern Pharmaceutical's indirect controlling shareholder China National.</i>
27-Oct	Livzon Pharmaceutical, Joicare Pharmaceutical end proposed asset restructuring (Source: Stock Exchange Announcement (Translated))	<i>The two China-based listed drug makers, Livzon Pharmaceutical [Li Zhu Yi Yao; SZ: 000513] and Joicare Pharmaceutical [Jian Kang Yuan; SHA: 600380] have terminated their proposed asset restructuring, according to stock exchange announcements posted on 27 October.</i>
27-Oct	Shanghai Modern Pharmaceutical confirms share trading halt amid significant assets restructuring	<i>Shanghai Modern Pharmaceutical [Xian Dai Zhi Yao; SH:600420], a listed Chinese pharmaceutical company, said tonight that its share trading halt will remain on 28 October as China National Pharmaceutical Group (Sinopharm) is planning a significant</i>

	planning (Source: Stock Exchange Announcement (Translated))	assets restructuring related to the listed company.
27-Oct	China National Accord Medicines to continue trading halt over proposed major asset restructuring (Source: Stock Exchange Announcement (Translated))	China National Accord Medicines [Guo Yao Yi Zhi; SZ: 000028], a listed pharmaceutical company, disclosed in a stock exchange announcement on 27 October that it will continue its trading halt as it is planning a major asset restructuring.
27-Oct	Fufeng proposes to spin off Shenhua Health for Hong Kong GEM board listing, JPMorgan named sole sponsor (Source: Stock Exchange Announcement(s) (Edited))	Fufeng Group [HKG: 0546], a Chinese food additive firm, has announced a proposed spin-off of its health product unit Shenhua Health for a listing on the Hong Kong bourse's GEM board. The Board is pleased to announce that the Company has submitted an application to the Stock Exchange pursuant to Practice Note 15 of the Listing Rules in relation to the Proposed Spin-off of Shenhua Health and has received written confirmation from the Stock Exchange on 16 October 2015.
27-Oct	Longshengtang Pharm 100% stake to be acquired by Tianjin Chasesun Pharmaceutical for CNY 60m (Source: Stock Exchange Announcement (Translated))	Tianjin Chasesun Pharmaceutical [Hong Ri Yao Ye; SZ: 300026], a Chinese listed company, has agreed to buy 100% of Longshengtang Pharm, a privately held Chinese patent drug maker, for CNY 60m (USD 9.456m), according to a stock exchange announcement. Tianjin Chasesun Pharmaceutical will acquire Longshengtang Pharm from its two owners including Zhou Wenqian.
27-Oct	Harbin Gloria plans CNY 4bn raise via private placement (Source: Stock Exchange Announcement (Translated))	Harbin Gloria Pharmaceuticals [Yu Heng Yao Ye] [SHE:002437], a listed Chinese pharmaceuticals company, said in a stock exchange announcement today that it is planning to raise up to CNY 4bn (USD 630m) via a private placement of new shares.
26-Oct	Suzhou Yangtze New Materials targets at Wuhan Hiteck Biological Pharmaceutical in planned major asset restructuring (Source: Stock Exchange Announcement (Translated))	Suzhou Yangtze New Materials (Yang Zi Xin Cai) [SZ: 002652], a China-based, listed pre-coated steel sheet maker, said in a stock exchange announcement on 26 October that it plans buy Wuhan Hiteck Biological Pharmaceutical [Hai Te Sheng Wu Zhi Yao]. Wuhan Hiteck is a privately owned company which produces nervous system disease medicines.
26-Oct	Australian Pharmaceutical shareholder Solomon Lew offloads stake – report (Source: Australian Financial Review)	Australian Pharmaceutical's [ASX: API] shareholder Solomon Lew has divested his stake in the Australian beauty and health retail firm, the Australian Financial Review reported. The paper's Street Talk column reported without citing sources that 60.28 million shares in Australian Pharmaceutical were traded.
26-Oct	Portea Medical says it is continually evaluating inorganic growth opportunities, declines comment on report of possible Medybiz Pharma buyout (Source: VCCircle)	Health Vista, the company that owns Portea Medical, the India-based home healthcare company, said it is continually evaluating inorganic growth opportunities, VCCircle, reported, citing K Ganesh, Portea's chairman. But Ganesh declined to comment on a report which said that Portea is now zeroing in on acquiring Medybiz Pharma, an Indian critical drugs transportation and delivery services company.
26-Oct	Guiyang Longmaster Information	Guiyang Longmaster Information and Technology [Lang Ma Xin Xi; SHE: 300288], a

	and Technology to acquire controlling interest in Guiyang Non. 6 People's Hospital as strategic investor (Source: Stock Exchange Announcement (Translated))	Guizhou-based, listed telecom and satellite services company, will acquire a controlling interest in Guiyang No.6 People's Hospital, a Guizhou-based hospital. According to the company stock exchange announcement today, it signed the framework agreement with the local government over becoming a strategic investor in Guiyang No.
24-Oct	Nanjing Xiejiakou Department Store signs LoI over buying stake in China Cord Blood (Source: Stock Exchange Announcement (Translated))	Nanjing Xinjiakou Department Store [Nan Jing Bai Huo; SHE: 600682], a China-based, listed department store operator, has signed an LoI with Golden Meditech [Jin Wei Yi Liao, HKG: 0801] over buying part of its stake in China Cord Blood Corporation. Golden Meditech is a major shareholder in China Cord Blood.
24-Oct	Starlake Bioscience terminates proposed acquisition of Hunan Xinhexin Biological Medicine and Heilongjiang Pharmaceutical (Source: Stock Exchange Announcement (Translated))	Starlake Bioscience (Xing Hu Ke Ji) [600866.SH], a Guangdong-based, listed food company, announced in a stock exchange announcement today that it has terminated the proposed acquisition of biopharmaceutical assets due to disagreements over deal price. As reported, the company planned to buy Hunan Xinhexin Biological Medicine [Xin He Xin], Heilongjiang Taihua Pharmaceutical [Hei Long Jiang Tai Hua Yi Yao], Anhui Wellman Pharmaceutical [Wei Er Man], and two other companies respectively.
23-Oct	ZCL Chemicals' 20% stake may be acquired by Kedaara Capital for INR 1.8bn - INR 2bn - report (Source: The Economic Times)	Around 20% stake in ZCL Chemicals, the Mumbai, India-based chemical and pharmaceutical company, is close to being acquired by private equity (PE) fund Kedaara Capital, The Economic Times (ET) reported. Kedaara Capital is nearly set to ink a buyout agreement worth around INR 1.8bn (USD 27.7m), citing two sources in-the-know, the paper noted. ZCL Chemicals is owned by India's Parikh family.
23-Oct	Theme International says MoU relating to acquisition of pharmaceutical businesses of Liberty International in China expired (Source: Stock Exchange Announcement*)	Theme International (HKG: 0990), a Hong Kong-based manufacturer and retailer of garments, announced that the memorandum of understanding relating to the acquisition of the pharmaceutical businesses of Liberty International in China has expired: This announcement is made by Theme International Holdings Limited (the "Company") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
23-Oct	EKF Diagnostics says Jinjing does not intend to make an offer (Source: Company Press Release(s))	EKF Diagnostics, the UK-based point-of-care, central laboratory and molecular diagnostics business, has announced that Jinjing Group has no intention of making an offer. An EKF statement said: The Board note the announcement by Jinjing (Group) Co., Ltd. that they do not intend to make an offer for the Company.
23-Oct	Unilabs attracts Sonic Healthcare, Novo, Cinven, PAI - report (Source: Newswire Round-up)	Unilabs, a Switzerland-based diagnostics firm, has attracted the interest from Australia's Sonic Healthcare [ASX: SHL] and Denmark-based Novo Nordisk's [CPH: NOVO-B] biggest stakeowner Novo A/S, according to a newswire report.
22-Oct	Zhongyuan Union Cell and Gene Engineering, Beijing Enterprises Medical and Health Industry form acquisition JV (Source: Stock Exchange Announcement (Translated))	Zhongyuan Union Cell and Gene Engineering [Zhong Yuan Xie He; SHA: 600645], a listed Chinese bioengineering technology company, and the Hong Kong-listed Beijing Enterprises Medical and Health Industry Group (HKG: 2389) signed a strategic cooperation agreement on 21 October.

22-Oct	Estia Health may be preparing acquisition, possible targets include Allity, Opal Aged Care, Kennedy Health and Oceania - report (Source: Australian Financial Review)	<i>Estia Health [ASX: EHE] may be preparing to announce an acquisition as early as next month, the Australian Financial Review's Street Talk reported. According to the report, which did not cite its sources, Estia could use cash, its shares, or a combination thereof to pursue its target. The item named Allity, the aged care business owned by Archer Capital, Opal Aged Care, owned by AMP Life and GK Goh Holdings, and Kennedy Health Care as possible targets. The paper noted that New Zealand-based Oceania could also be a target.</i>
22-Oct	Health Care bidders may include Mulpha International and IFM Investors - report (Source: Australian Financial Review)	<i>Mulpha International [KLSE: MULPHA] and IFM Investors are believed to be among bidders for Health Care, the Australian hospital operator, the Australian Financial Review reported. According to the unsourced report in the paper's Street Talk column, both groups are said to have received an information memorandum.</i>
22-Oct	Shinva Medical Instrument plans private placement; proceeds could be used to buy medical device and service sector assets (Source: Stock Exchange Announcement (Translated))	<i>Shinva Medical Instrument [Xin Hua Yi Liao; SHE:600587], a China-based medical device manufacturer and distributor, is planning a private placement and part of the proceeds could be used to buy assets in medical device and services sectors, according to a stock exchange announcement.</i>
22-Oct	Beijing Kangyuan Pharmaceutical to be sold to Shanxi Zhendong (Source: Stock Exchange Announcement (Translated))	<i>Shanxi Zhendong Pharmaceutical [Zhen Dong Zhi Yao; SZ: 300158], a listed Chinese entity, signed an agreement 21 October to acquire the 100% stake in Beijing Kangyuan Pharmaceutical for CNY 2.646bn (USD 418.8m), according to a stock exchange announcement. Beijing Kangyuan is a calcium preparation drug producer controlled by individual investor Li Xun, the Chinese-language announcement said.</i>
22-Oct	S&P Pharmaceutical to be sold by Far East Smarter Energy to Tibet Rong'en Technology for USD 50.4m (Source: Stock Exchange Announcement (Translated))	<i>Far East Smarter Energy [Zhi Hui Neng Yuan; SH: 600869], a China-based listed company, has signed an agreement to transfer 100% of S&P Pharmaceutical [San Pu Yao Ye] to Tibet Rong'en Technology [Rong En Ke Ji] for CNY 320m (USD 50.4m), according to a stock exchange announcement dated 22 October.</i>
22-Oct	Shanghai Fosun Pharmaceutical and Tebon Innovation to jointly acquire 20% of Sinopharm Holding Medical Investment Management for up to approximately CNY 114m (Source: Stock Exchange Announcement*)	<i>Shanghai Fosun Pharmaceutical (HKG: 2196), a Chinese pharmaceutical company, announced that the company and Tebon Innovation have signed a joint acquisition agreement to acquire 20% of Sinopharm Holding Medical Investment Management for up to approximately CNY 114m (USD 18m): References is made to the overseas regulatory announcement of the Company dated 26 June 2014 in relation to the proposed acquisition of 35% equity interest in Sinopharm Medical Investment through bidding and tendering on CBEX for a consideration of not more than CNY 200m.</i>
22-Oct	SM Group seeks to acquire Austin Pharm - report (translated) (Source: Korea Economic Daily)	<i>South Korean conglomerate SM Group is seeking to acquire Austin Pharm, a local distressed pharmaceutical company, reported Korea Economic Daily. Tongyang Life Science, a cosmetic making division of SM Group, has offered the highest bid in the sale of Austin Pharm, the Korean-language report cited insiders from EY.</i>
22-Oct	Strides Arcolab to acquire seven brands from Johnson & Johnson, majority stake in domestic	<i>Strides Arcolab (NSE: STAR, BOM: 532531) on 21 October 2015 informed the NSE that it has entered into agreements for two independent transactions, which will strengthen the Company's India branded business. a) Acquisition of seven brands from</i>

	branded business of Medispan <i>(Source: Stock Exchange Announcement(s) (Edited))</i>	<i>Johnson & Johnson Products across dermatology, anti-emetic and pain management segments, to be launched immediately.</i>
21-Oct	Estia shareholders Quadrant and Mercury expected to exit – report <i>(Source: The Australian)</i>	<i>Quadrant Private Equity and Mercury are expected to exit a portion of their combined AUD 260.4m (USD 188.9m) in Estia Health [ASX: EHE], The Australian’s Dataroom reported. According to the unsourced report, Quadrant may be unwilling to give up its board position due to Estia’s possible offer for Allity, which is owned by Archer Capital.</i>
21-Oct	Chularat Hospital to buy hospital, plans more acquisitions next year (translated) <i>(Source: Thunhoon)</i>	<i>Chularat Hospital [BKK: CHG], a Thailand-based hospital operator, is preparing to acquire a hospital which has the same size as the company, Thunhoon reported. The Thai-language report cited Managing Director Kumpol Plussind as saying.</i>
21-Oct	Pacific Equity Partners, Healthscope out of competition for Healthe Care - report <i>(Source: Australian Financial Review)</i>	<i>Pacific Equity Partners, which was seen among the suitors of Healthe Care, has withdrawn from the second-round of auction for the Australia-based hospital operator, leaving KKR [NYSE: KKR] and Bain Capital in competition, the Australian Financial Review reported in its Street Talk column.</i>
21-Oct	First Real Estate Investment Trust enters into proposed joint arrangement and asset swap with PT Saputra Karya <i>(Source: Stock Exchange Announcement*)</i>	<i>First Real Estate Investment Trust (SGX: AW9U) has entered into a proposed joint arrangement and asset swap with PT Saputra Karya, according to a stock exchange announcement. Bowsprit Capital Corporation Limited (“Bowsprit”), the Manager of First Real Estate Investment Trust (“First REIT” or the “Trust”).</i>
20-Oct	MP Biomedicals to be sold to Valiant for USD 142.5m: UPDATE <i>(Source: Stock Exchange Announcement (Translated))</i>	<i>The headline on this article has been changed to reflect the US dollar deal value. At today’s rate USD 142.5m is CNY 904m, not CNY 850m, which is the amount the company will take from the non-public shares offering to fund the deal. Valiant (Wan Run Gu Fen) [SZ: 002643], a listed, China-based, maker of fine chemicals.</i>
20-Oct	Chang Jiang Runfa Machinery proposes to buy pharmaceutical assets from controlling shareholder; Huatai United advising <i>(Source: Stock Exchange Announcement (Translated))</i>	<i>Chang Jiang Runfa Machinery (Chang Jiang Run Fa) [SZ: 002435], a China-based, listed elevator components maker, is in talks to buy Changjiang Runfa Zhangjiagang Bonded Area Medical Investment, an SPV owned by Changjiang Runfa Group. According to a stock exchange announcement dated 20 October, the SPV, set up by Changjiang Runfa Group, owns three pharmaceutical companies.</i>
20-Oct	Care Hospitals' winning bidder likely to be announced within two weeks – report <i>(Source: The Economic Times)</i>	<i>India-based Care Hospitals is expected to announce the winning bidder for acquiring controlling stake in the multi-specialty healthcare chain of hospitals within two weeks, The Economic Times reported, citing a source in-the-know. According to the report, bids from suitors were offered in the range of INR 18bn - INR 20.2bn.</i>
20-Oct	Hengkang Medical, Chengdu University of TCM sign strategic partnership agreement over forming tumor treatment hospital <i>(Source: Stock Exchange Announcement (Translated))</i>	<i>Hengkang Medical [Heng Kang Yi Yuan; SZ: 002219], a China-based, listed pharmaceutical company, has signed a strategic partnership agreement with Chengdu University of TCM [Cheng Du Zhong Yi Yuan Da Xue], a Sichuan-based medical university, on 19 October.</i>
20-Oct	Apollo Health and Lifestyle	<i>Apollo Health and Lifestyle Ltd (AHLL), a subsidiary of India-based Apollo Hospitals</i>

	appoints Spark Capital to manage planned sale of 25% stake to PEs (Source: The Economic Times)	<i>Enterprise (BOM:508869), has appointed Spark Capital to manage the planned sale of 25% stake in AHLL to private equity (PE) funds, The Economic Times reported.</i>
20-Oct	Suraksha Diagnostic in talks with PEs for INR 2bn (USD 30.83m) growth capital raise – report (Source: Mint)	<i>Suraksha Diagnostic, a Kolkata, India-based medical diagnostics chain, has initiated talks with private equity (PE) investors for raising a minimum INR 2bn (USD 30.83m) for growth capital purposes, mint reported, citing two sources with knowledge of the situation. The company has already appointed an undisclosed, boutique investment bank based in Mumbai.</i>
20-Oct	CHTC Helon targeting medical imaging companies for acquisition (Source: Stock Exchange Announcement (Translated))	<i>CHTC Helon [Heng Tian Hai Long; SZ:000677], a China-based, viscose fibre producer, said in a stock exchange announcement today (October 20) that it is actively pursuing its acquisition targets with the help of its financial advisor Cinda Securities. Acquisition targets include companies engaged in the manufacturing and sales of medical imaging equipment including CT, PET-CT, and MRI.</i>
20-Oct	Shanghai Modern Pharmaceutical to halt share trading on 21 October, significant assets restructuring possible (Source: Stock Exchange Announcement (Translated))	<i>Shanghai Modern Pharmaceutical [Xian Dai Zhi Yao; SH:600420], a listed Chinese pharmaceutical company, said in a stock exchange announcement tonight that its indirect controlling shareholder China National Pharmaceutical Group (Sinopharm) is planning a major event regarding the listed company.</i>
20-Oct	Recipharm inks deal to acquire 74% stake in Nitin Lifesciences (Source: The Economic Times)	<i>Recipharm (STO:RECI), the Sweden-based contract development and manufacturing organisation, announced on 20 October 2015 that it has entered into an agreement whereby it will acquire a majority stake in Nitin Lifesciences (“Nitin”).</i>
19-Oct	Qingdao Huaren Pharmaceutical ends proposed acquisition of Qingdao Huaren Tery Pharmaceutical (Source: Stock Exchange Announcement (Translated))	<i>Qingdao Huaren Pharmaceutical [300110: CH], a China-based maker and distributor of infusion products, has terminated the proposed purchase of Qingdao Huaren Tery Pharmaceutical [Hua Ren Tai Yi Yao], according to a stock exchange announcement made on 19 October.</i>
19-Oct	Winshine Entertainment & Media signs MoU for possible 70% stake acquisition in Beijing Wufangqiao Chinese Medicine Kidney Disease Hospital (Source: Stock Exchange Announcement(s))	<i>Winshine Entertainment & Media Holding (HKG:0209), a Hong Kong-based toys manufacturer, announced that it has signed a non-legally binding memorandum of understanding for the possible acquisition of a 70% stake in Beijing Wufangqiao Chinese Medicine Kidney Disease Hospital Company Limited: This announcement is made by Winshine Entertainment & Media Holding Company Limited.</i>
19-Oct	Endospan 10.75% stake to be sold to Xizang Haisco Pharmaceutical Group subsidiary HaisThera (Source: Stock Exchange Announcement (Translated))	<i>HaisThera, a subsidiary of Xizang Haisco Pharmaceutical Group [Hai Si Ke; SZE:002653], a China-based, listed company, has signed an agreement to buy a 10.75% stake in Endospan, the Israel-based medical device maker, for USD 10m, according to a stock exchange announcement dated 19 October.</i>
19-Oct	Southern Specialist Eye Centre to be acquired by ISEC Healthcare	<i>ISEC Healthcare (SGX: 40T), the Malaysia-based medical eyecare service provider, has agreed to acquire Southern Specialist Eye Centre, according to a stock exchange</i>

19-Oct	(Source: Stock Exchange Announcement(s) (Edited)) Srivichai Vejvivat denies takeover report - report (translated) (Source: Thunhoon)	announcement. 1. INTRODUCTION The Board of Directors (the “Board”) of ISEC Healthcare Ltd. Srivichai Vejvivat [BKK: VIH], a Thailand-based medical services provider, has denied the rumor that the company has attracted an investor to take over and form joint venture with the company, Thunhoon reported.
18-Oct	Humanwell Healthcare, Yichang Health and Family Planning Commission to form a hospital management JV on a 34:66 basis (Source: Stock Exchange Announcement (Translated))	Humanwell Healthcare [Ren Fu Yi Yao, SHE:600079], a listed, Chinese pharmaceutical company, and Yichang Health and Family Planning Commission, a Hubei-based local government agency, plan to form a hospital management JV on a 34:66 basis.
18-Oct	Hengkang Medical Group signs Lol on buying overseas peer company (Source: Stock Exchange Announcement (Translated))	Hengkang Medical Group [Heng Kang Yi Yuan; SZ: 002219], a China-based, pharmaceutical company, has signed an Lol on buying an overseas peer company. According to the company stock exchange announcement tonight, a preliminary agreement has been reached on the proposed acquisition and the proposed deal will be qualified for a significant assets restructuring.
17-Oct	Zhejiang Shapuaisi Pharmaceutical to halt share trading on 19 October over potential assets purchase (Source: Stock Exchange Announcement (Translated))	Zhejiang Shapuaisi Pharmaceutical [Sha Pu Ai Si; 603168.SH], a Zhejiang, China-based pharmaceutical company, will enter into a share trading halt on 19 October over potential assets purchase via new share issuance. According to the company's stock exchange announcement today, the company will seek to finalize whether to proceed with the proposed deal and is expecting to disclose the progress over the proposed deal within five working days.
16-Oct	IHH Healthcare enters JV with Shanghai Broad Ocean Investments to operate 350-bed hospital in Chengdu (Source: Company press release(s) (Edited))	IHH Healthcare [KLSE: 5225], the Malaysian healthcare provider, is teaming up with Shanghai Broad Ocean Investments to operate a 350-bed tertiary hospital in Chengdu, China. IHH on 15 October issued the following press release on the matter. IHH Healthcare Berhad (“IHH” or the “Group”), through its indirect wholly owned subsidiary, M & P Investments Pte Ltd (“M&P”), and its local Chinese partner.
15-Oct	Jianjin Medicine 90% stake priced at CNY 145m by Sunflower Pharmaceutical (Source: Stock Exchange Announcement (Translated))	Sunflower Pharmaceutical (Kui Hua Yao Ye) [SZA:002737], a China-based, listed pharmaceutical company, priced the 90% stake in Jianjin Medicine [Jian Jin Yi Yao] that it would buy from Shanghai Zhongmin Yuhao [Zhong Min Yu Hao] at CNY 145m (USD 15.84m).
15-Oct	Hangzhou Tianmushan Pharmaceutical in talks over buying stake in a pharmaceutical company via cash payment (Source: Stock Exchange Announcement (Translated))	Hangzhou Tianmushan Pharmaceutical [Tian Mu Shan; 600671.SH], the Zhejiang-based listed pharmaceuticals company, said in a stock exchange announcement tonight that its share trading halt will remain on 16 October. The company is planning to buy stake in a pharmaceutical company from a third-party company and the proposed acquisition is expected to be completed via cash payment.
15-Oct	Tonghua Grape Wine drops proposed pharma acquisition (Source: Stock Exchange	Tonghua Grape Wine [Tong Pu Gu Fen;SHA:600365], the Chinese winemaker, said in a stock exchange announcement on 15 October that it has terminated a major asset restructuring that targeted a pharmaceutical company. As reported, Tonghua Grape

	Announcement (Translated))	<i>Wine entered into a trading halt 16 July over the proposed restructuring.</i>
15-Oct	Vista Land & Lifescapes planning to enter healthcare sector through joint ventures (Source: Philippine Star)	<i>Philippine-listed Vista Land & Lifescapes [PSE: VLL] is planning to enter the healthcare sector through joint ventures, reported the Philippine Star citing Manuel Villar, the founder of Vista Land. A report in the Manila Times also cited Villar who expected the company to post steady sales for 2015.</i>
15-Oct	Guizhou Yibai Pharmaceutical to take a 51% stake in a medical JV (Source: Stock Exchange Announcement (Translated))	<i>Guizhou Yibai Pharmaceutical [Yi Bai Zhi Yao; SHA:600594], a listed Chinese company, said in a stock exchange announcement today that it has signed the framework agreement over forming a medical JV on 14 October. According to the announcement, Shanghai Yibai Tumor Medical Investment Management [Shang Hai Yi Bai Yi Liao Tou Zi Guan Li], the JV, will have a registered capital of CNY 100m (USD 15.7m).</i>
14-Oct	Guangxi Investment may buy Guangxi Wuzhou Zhongheng 21% stake from Guangxi Zhongheng Industry (Source: Stock Exchange Announcement (Translated))	<i>Guangxi Zhongheng Industry has signed a letter of intent to transfer a 20.52% stake in Guangxi Wuzhou Zhongheng Group [Zhong Heng Ji Tuan; SHA: 600252], a listed Chinese pharmaceutical company, to Guangxi Investment Group. Under the Lol, related parties are expected to sign a formal agreement on or before 30 November, but the actual signing date is subject to factors such as the result of due diligence.</i>
14-Oct	R-Tech Ueno says Sucampo Pharmaceuticals successfully completes tender (Source: Stock Exchange Announcement (Translated))	<i>R-Tech Ueno [TYO: 4573], announced today [14 October] that Sucampo Pharmaceuticals [NASDAQ:SCMP] had successfully completed its tender offer for shares in the company. Sucampo targeted 11,068,948 shares in the tender offer, with the minimum level of acceptances set at 5,534,575 shares.</i>
14-Oct	Hangzhou Tianmushan Pharmaceutical 16.77% stake to be sold to GREATWALL Movie & Television Cultural Corp Group (Source: Stock Exchange Announcement (Translated))	<i>A 16.77% stake of Hangzhou Tianmushan Pharmaceutical [Tian Mu Shan;600671.SH], the China-based listed pharmaceuticals company, will be sold to GREATWALL Movie & Television Cultural Corp Group [Chang Cheng Ji Tuan] for CNY 500m (USD 78.77m).</i>
14-Oct	Zhangzhou Pientzhuang Pharmaceutical and Citic Prosperity Fund form CNY 500m buyout fund focused on traditional Chinese medicine, health sectors (Source: Stock Exchange Announcement (Translated))	<i>Zhangzhou Pientzhuang Pharmaceutical [Pian Zai Huang; SHA: 600436] and Citic Prosperity Fund [Xin Ye Gu Quan Tou Zi Guan Li], a Beijing-based fund management company, have signed an agreement through which they will form a buyout fund.</i>
14-Oct	Health Care suitor Bangkok Dusit out of the race - report (Source: The Australian)	<i>Bangkok Dusit [BKK: BDMS] is said to be out of the running to buy Health Care, the Australia-based hospital operator, The Australian's Dataroom reported. According to the report, which did not cite sources, Health Care is expected to receive bids today from Bain Capital, Pacific Equity Partners, and KKR [NYSE: KKR].</i>
14-Oct	Helius Medical Technologies inks sale and licensing deal with A&B Co on PoNSTM device (Source: Company Press Release(s))	<i>Newtown, Pennsylvania-based Helius Medical Technologies (OTCQB: HSDT) has entered into an agreement with Hong Kong-based A&B Company for a sale and licensing transaction around its PoNSTM device. The company stated as follows: Helius Medical Technologies Inc.</i>

14-Oct	Bumrungrad Hospital, Yangon International Medical to set up JV in Myanmar (Source: Stock Exchange Announcement(s) (Edited))	<i>Bumrungrad Hospital [BKK:BH], a Thailand-based hospital operator, announced that it will set up a hospital joint venture in Myanmar, according to the following stock exchange statement: Bumrungrad Hospital Public Company Limited (“the Company”) would like to inform that, according to the meeting of the Investment Committee’s.</i>
14-Oct	SDIC Xinji Energy planning to sell Huainan Xinkang Hospital (Source: Stock Exchange Announcement (Translated))	<i>SDIC Xinji Energy [Guo Tou Xin Ji; SH: 601918], an Anhui-based listed electric power company, said in a stock exchange announcement today that its board meeting has approved to sell Huainan Xinkang Hospital [Huai Nan Xin Kang Yi Yuan].</i>
14-Oct	Hengkang Medical to buy 72.6% stake in The Second People's Hospital of Chongzhou City (Source: Stock Exchange Announcement (Translated))	<i>Hengkang Medical Group [Heng Kang Yi Yuan; SZ:002219], a China-based, pharmaceutical company, has signed a framework agreement to buy a 72.61% stake in The Second People's Hospital of Chongzhou City from individual investor Zhu Zhizhong.</i>
13-Oct	Health Care targeted by Champ Private Equity - report (Source: The Australian)	<i>Champ Private Equity is said to be interested in Health Care, the Australia-based hospital operator, The Australian’s Dataroom reported. According to the report, which did not cite sources, bids for Health Care, which is being sold by Archer Capital, are due tomorrow.</i>
13-Oct	COL Capital acquires Jiati Construction 39.48% stake and Aveo China 40% stake (Source: Stock Exchange Announcement (Translated))	<i>COL Capital Limited (HKG: 383), the Hong Kong-listed financial services and property investment company, announced an acquisition of 39.48% stake in Lianyungang Jiatai Construction Co. Ltd and 40% stake in Aveo China (Holdings) Limited.</i>
13-Oct	First REIT sees new acquisition opportunities in Indonesia (Source: Stock Exchange Announcement*)	<i>First Real Estate Investment Trust (“First REIT”) [SGX: AW9U], the Singapore-listed healthcare REIT, is continuing to be presented with Indonesian acquisition opportunities, according to a stock exchange announcement. The government unveiled a series of stimulus measures aimed at attracting more investment, boosting consumer spending and supporting the rupiah.</i>
13-Oct	Chtc Helon plans to buy medical equipment-related assets, plans to hire Cinda Securities as financial advisor (Source: Stock Exchange Announcement (Translated))	<i>Chtc Helon [Heng Tian Hai Long; SZ: 000677], a China-based, listed viscose fibre producer, said in a stock exchange announcement today that it is planning to buy assets in medical equipment sector in addition to its planned significant assets restructuring.</i>
13-Oct	Cosmax BTI denies report it is seeking to acquire Naturalendo Tech (Source: Stock Exchange Announcement (Translated))	<i>Cosmax BTI (KRX: 044820), the South Korean cosmetics manufacturer, has denied a news report that it is seeking to acquire Naturalendo Tech (KOSDAQ: 168330), a South Korea-based hormone biotechnology products maker. According to its statement to the stock exchange on 13 October, it has not considered such a deal.</i>
13-Oct	Anhui Fengyuan Pharmaceutical plans to buy Chengdu Push Pharmaceutical stake (Source: Stock Exchange Announcement)	<i>Anhui Fengyuan Pharmaceutical [Feng Yuan Yao Ye, 000153.SZ], a listed Chinese pharmaceutical company, plans to buy a stake of Chengdu Push Pharmaceutical from Sichuan Yibin Push Group. Anhui Fengyuan Pharmaceutical will halt trading on 14 October and publish the deal plan on 12 November, Anhui Fengyuan Pharmaceutical</i>

*(Translated))**disclosed in a stock exchange announcement dated 13 October.*

13-Oct	Shionogi to spin off OTC drug operations in 2016 (Source: Company Press Release(s))	<i>Shionogi & Co Ltd. [TYO:4507], a Japanese pharmaceutical maker, plans to spin off its over-the-counter (OTC) drug operations after forming a consumer healthcare company in January 2016, the Osaka-based company said in a press statement.</i>
13-Oct	Shanghai Xingao Feng Biotech to be sold to Zhejiang Yatai Pharmaceutical for USD 142m (Source: Stock Exchange Announcement (Translated))	<i>Zhejiang Yatai Pharmaceutical [Ya Tai Yao Ye; SZ: 002370], a China-based listed pharmaceutical company, has signed an agreement on 10 October to acquire 100% of Shanghai Xingao Feng Biotech for CNY 900m (USD 142m), according to a stock exchange announcement posted today.</i>
13-Oct	Kalbe Farma forms joint venture with Korea's Genexine (Source: Stock Exchange Announcement (Translated))	<i>Kalbe Farma, the listed Indonesian pharmaceuticals company, has signed an agreement with Korea's Genexine for the formation of a joint venture company based in Indonesia, according to a stock exchange announcement. The announcement said that Kalbe holds a 60% stake in the new company, PT Kalbe-Genexine Biologics, while Genexine owns a 40% stake, with an initial investment of IDR 130bn (USD 9.6m).</i>
13-Oct	Guangxi Future Technology's CNY 2.35bn fundraising plan rejected by CSRC (Source: Stock Exchange Announcement (Translated))	<i>Guangxi Future Technology [Hui Qiu Ke Ji; SH:600556], formerly called Guangxi Beisheng Pharmaceutical, said in a stock exchange announcement today that its proposed CNY 2.35bn (USD 372m) private placement plan has been rejected by the China Securities Regulatory Commission (CSRC).</i>
12-Oct	Shenzhen Hepalink Pharmaceutical to form JV with partners including OncoQuest (Source: Stock Exchange Announcement (Translated))	<i>Shenzhen Hepalink Pharmaceutical [Hai Pu Rui; SZA:002399], a China-based biological products company, said in a October 19 stock exchange announcement that it is planning to form a joint venture in China with partners including OncoQuest.</i>
12-Oct	Unichem Labs denies reports that it will sell its India-based formulations business - report (Source: The Economic Times)	<i>Unichem Labs [BOM: 506690], the India-based pharmaceutical company, has denied that it has plans to sell its domestic formulations business, The Economic Times reported, citing a corporate statement. Unichem also denied appointing an advisor for the alleged sale plan.</i>
12-Oct	Orchid Chemicals & Pharmaceuticals board allots 3,702,450 shares to principal shareholder group company under CDR scheme (Source: Stock Exchange Announcement(s) (Edited))	<i>The India-based Orchid Chemicals & Pharmaceuticals' (BOM: 524372) board has allotted 3,702,450 shares to a principal shareholder group company under the Company's Corporate Debt Restructuring (CDR) Scheme. Orchid Chemicals & Pharmaceuticals.</i>
12-Oct	Shenzhen Success Electronics enters share trading halt, plans to acquire part or all of Wego Holding (Source: Stock Exchange Announcement (Translated))	<i>Shenzhen Success Electronics [Yu Shun Dian Zi; 002289:SZ], a listed electronic components manufacturer, said in a stock exchange announcement dated 12 October that its share trading halt will be halted from the day onwards, as it is planning to buy assets via new share issuance and cash payment. The target assets will be part or all of the stakes in the intelligent medical equipment subsidiaries of Wego Holding [Wei Gao Ji Tuan], a Shandong-based privately held medical equipment manufacturer.</i>

12-Oct	Shenzhen Yushun Electronics to acquire intelligent medical equipment business from Weigao Holding (Source: Stock Exchange Announcement (Translated))	Shenzhen Yushun Electronics (Yu Shun Dian Zi) [SZ:002289], a China-based listed electronic product maker, disclosed in a stock exchange announcement on 12 October that it plans to acquire an intelligent medical equipment business from Weigao Holding.
12-Oct	Astute Medical receives USD 20m investment from Shanghai Fosun Pharmaceutical (Source: Company Press Release(s) (Edited)) Sanad Hospital's additional 57% acquired by Azad Moopen's Aster DM Healthcare for INR 16bn (Source: The Economic Times)	Astute Medical, Inc. today announced the signing of an agreement with Shanghai Fosun Long March Medicine Science Co. Ltd. (Fosun Long-March), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (FOSUNPHARMA), for distribution of Astute's NephroCheck® Test on the Astute140® Meter in China. Aster DM Healthcare, a health segment company owned by non-resident Indian (NRI) investor Azad Moopen, has acquired an additional 57% stake-holding in Sanad Hospital, the Riyadh, Saudi Arabia-based hospital, for INR 16bn (USD 246.88m), The Economic Times reported.
11-Oct	Health Care vendor targeting infrastructure investors as possible buyers – report (Source: The Australian)	Infrastructure investors are being targeted as possible buyers for Health Care, the Australian hospital operator, The Australian's Dataroom reported. According to the report, which did not cite sources, New Zealand's Morrison & Co is thought to be looking at the target and has taken an information memorandum.
11-Oct	Sundiro planning to form a medical buyout JV with its ultimate controller and Ch-gemstone Capital Holdings (Beijing) (Source: Stock Exchange Announcement (Translated))	Sundiro [Xin Da Zhou; SH: 000571], a Hainan-based, listed coal company, signed a framework agreement with its ultimate controller Mr. Zhao Xuhong and Ch-gemstone Capital Holdings (Beijing) Co.,Ltd. [Zhong Yu Zi Ben Guan Li Bei Jing] over forming a medical buyout fund.
10-Oct	Guangxi Zhongheng Industry in talks to sell Guangxi Wuzhou Zhongheng Group stake, local company likely to buy - report (translated) (Source: China Business Journal)	Guangxi Zhongheng Industry is in talks with a Guangxi-headquartered company over the sale of a stake in Guangxi Wuzhou Zhongheng Group [Zhong Heng Ji Tuan; SHA:600252], a listed Chinese pharmaceutical company, China Business Journal reported, citing a person close to Zhongheng Industry. As reported, Guangxi Zhongheng Industry has pledged a 20.40% stake for a loan of CNY 370m (USD 58.3m).
9-Oct	Starlake Bioscience share trading halt remains over biopharmaceutical assets purchase (Source: Stock Exchange Announcement (Translated))	Starlake Bioscience (Xing Hu Ke Ji) [600866.SH], a Guangdong-based, listed food company, has been in a share trading halt since 19 March as the company is planning to buy biopharmaceutical assets. According to the company stock exchange announcement tonight, it has completed due diligence on Hunan Xinxin Biological Medicine [Xin He Xin], Heilongjiang Taihua Pharmaceutical.
9-Oct	Shandong Realcan Pharmaceutical plans to raise up to USD 488m via private placement of new shares (Source: Stock Exchange Announcement (Translated))	Shandong Realcan Pharmaceutical [Rui Kang Yi Yao; SZ:002589], a Shandong, China-based, listed pharmaceutical company, said in a stock exchange announcement today that its board has approved a non-public offering of CNY 3.1bn (USD 488m). Shandong Realcan Pharmaceutical plans to issue new shares at no less than a 90% of its average trading price in the last 20 trading days, and the proceeds will be used to fund the nationwide marketing network of medical equipment and the hospital supply chain management projects.

9-Oct	AFT Pharmaceuticals confirms plans to conduct IPO on the NZX and ASX (Source: The National Business Review)	<i>AFT Pharmaceuticals, the New Zealand-based drug maker, has confirmed plans to conduct an initial public offering (IPO) on the NZX and ASX, reported the National Business Review, citing Hartley Atkinson, the founder of AFT. First NZ Capital is advising the company for the possible capital raising.</i>
9-Oct	ZH International to acquire Crescent Medical Centre for USD 20.5m (Source: Stock Exchange Announcement*)	<i>ZH International (HKG: 0185), a Hong Kong-based hotel operations and property development company, announced that Global Medical REIT, a 99%-owned subsidiary of the company, has signed an agreement to acquire a hospital named as Crescent Medical Centre located at 2600 West Pleasant Run Road, Lancaster, Texas 75146, United States (the "Medical Facility"), for USD 20,500,000.</i>
9-Oct	Fortis denies report of SRL Diagnostics look at all strategic options, beyond just the proposed share sale by SRL's minority stakeowners (Source: The Times of India)	<i>India's Fortis Healthcare [BOM:532843] has denied a report in the press which said that New Delhi, India-based SRL Diagnostics may consider looking at all the strategic options on the table, beyond just the proposed share sale by SRL's minority stakeowners.</i>
9-Oct	Apollo Health and Lifestyle plans to invest up to INR 5bn to fund business growth, intends to invite PE investors to participate (Source: Stock Exchange Announcement(s) (Edited))	<i>The India-based Apollo Hospitals Enterprise (BOM:508869) informed the BSE on 08 October 2015 about the following with regard to the fundraising plans of the Company's subsidiary, Apollo Health and Lifestyle Ltd (AHLL). "AHLL operates a network of primary care and specialty care formats across India.</i>
9-Oct	Saket City Hospitals sale being discussed, valued at INR 10bn (USD 153.7m) - report (Source: Mint)	<i>Bhupendra Kumar Modi, owner of India-based Saket City Hospitals, is in talks with Manipal Health Enterprises and Max Health Enterprises over a possible sale, mint reported, citing two sources with knowledge of the situation. Several unnamed foreign hospital chains are also engaged in talks, the report said.</i>
9-Oct	Zhejiang Jolly and Deqing Health Bureau form 75:25 JV (Source: Stock Exchange Announcement (Translated))	<i>Zhejiang Jolly Pharmaceutical [Zuo Li Yao Ye; SZ: 300181], the China-based pharma company, and Deqing Health and Family Planning Bureau, a Chinese government agency, have signed the agreement over forming a hospital JV. According to the Zhejiang Jolly Pharmaceutical stock exchange announcement, Deqing New Third Hospital, the JV, will have a registered capital of CNY 252.36m (USD 39.72m).</i>
8-Oct	Modern Medical to be acquired by BGD (Source: Stock Exchange Announcement(s) (Edited))	<i>BGD Corporation Limited [ASX: BGD] has entered into a binding Heads of Agreement to acquire certain businesses and assets of Modern Medical Pty Ltd (MMG), a provider of primary healthcare services, BGD said in a statement filed to the Australian Securities Exchange, as follows. The transaction is still subject to various conditions precedent including satisfactory due diligence, BGD conducting a capital raising, regulatory and shareholder approvals.</i>
8-Oct	CARE Hospitals: Temasek-TPG Growth's combined bid is higher than Abraaj's, both bids are still in contention - report (Source: The Times of India)	<i>Temasek and TPG Growth have submitted a combined bid that is higher than that from rival suitor Abraaj for Advent International's stake in India-based CARE Hospitals, Times of India reported without citing sources.</i>

8-Oct	Apollo Health and Lifestyle looks raise up to INR 5bn (USD 77m) from PEs - report (Source: The Economic Times)	Apollo Health and Lifestyle (AHL), a wholly owned arm of India's Apollo Hospitals Group [BOM: 508869], is seeking to raise INR 3bn-INR 5bn (USD 46.1m-USD 76.8m) from private equity (PE) investors, The Economic Times reported. Sangita Reddy, Apollo Hospitals' joint managing director, was cited as saying that AHL would proceed soon with its fundraising plans.
8-Oct	Singapore Medical signs non-binding MoU with Cardioscan on proposed JV (Source: Stock Exchange Announcement*)	Singapore Medical Group (SMG) [SGX: 50T], the Singapore-listed healthcare provider, has entered into a non-binding memorandum of understanding with Cardioscan for a proposed joint venture, according to a stock exchange announcement. The Board of Directors (the "Board") of Singapore Medical Group Limited.
8-Oct	AbClon files KOSDAQ IPO application; NH Investment & Securities acting as manager (Source: Stock Exchange Announcement (Translated))	AbClon, a South Korean pharmaceutical company, has filed an application for regulatory approval for a proposed IPO, according to a Korea Exchange (KRX) statement today. The company plans to float on the KOSDAQ. It aims at raising KRW 12.9bn (USD 11m) from the listing.
7-Oct	Zalicus Pharmaceuticals acquired by Taro Pharma from EPIRUS Biopharmaceuticals (Source: Regulatory Authority Press Release (edited))	Epirus Biopharmaceuticals [NASDAQ:EPRS] has announced the following, pertaining to the sale of its subsidiary, Zalicus Pharmaceuticals Ltd, to Taro Pharmaceuticals Inc [NYSE:TARO]. The release states: On October 1, 2015, EPIRUS Biopharmaceuticals, Inc. (the "Company") entered into and closed a Share Purchase Agreement (the "Purchase Agreement") with Taro Pharmaceuticals Inc.
7-Oct	Sun Pharmaceutical Industries proposes to raise up to INR 120bn via QIP, convertible debentures (Source: Stock Exchange Announcement(s) (Edited))	Sun Pharmaceutical Industries [BOM: 524715], the Indian pharma, is seeking clearance from its shareholders for raising up to INR 120bn (USD 1.84bn) through qualified institutional placement (QIP), convertible bonds/debentures, among other routes.
7-Oct	Sun Pharma seeks shareholders' nod for raising INR 500bn for acquisitions (Source: Stock Exchange Announcement(s) (Edited))	Sun Pharmaceutical Industries [BOM: 524715], the Indian pharma, said it is seeking clearance from its shareholders for raising up to INR 500bn (USD 7.66bn), which the company could use for making acquisitions. This information was contained in a stock exchange filing, available here According to the announcement.
6-Oct	ZH International to acquire Star Medical Center Hospital for USD 17.5m (Source: Stock Exchange Announcement*)	ZH International (HKG: 0185), a Hong Kong-based hotel operations and property development company, announced that it has signed an agreement to acquire Star Medical Center Hospital located at 4100 Mapleshade Lane, Plano, Texas 75075.
6-Oct	Benchmark Systems acquired by Antworks for an estimated USD 5.1m (Source: The Economic Times)	Antworks, a Singapore-based BPO company, has acquired Benchmark Systems, the US-based healthcare applications services provider, The Economic Times reported. The all-cash buyout was transacted at around INR 330m (USD 5.1m), the paper said.
5-Oct	Sunbio files application for KOSDAQ IPO (Source: Stock Exchange Announcement (Translated))	Sunbio, the South Korean biosimilar and biotechnology company, has filed an application for regulatory approval for a proposed IPO, according to a Korea Exchange (KRX) statement disclosed today. The company plans to float on the KOSDAQ. CEO Kwang Roh owns 40% of the company.

5-Oct	Longrun Tea Group to sell Yunnan Long Far Pharmaceutical for HKD 52m (Source: Stock Exchange Announcement(s))	Longrun Tea Group [HKG: 2898], a Chinese tea company, announced that it has signed an agreement to sell Yunnan Long Far Pharmaceutical Company Limited to its controlling shareholder for HKD 52m (USD 6.7m).
5-Oct	U&I to launch KRW 37.5bn IPO on 2 November (Source: Stock Exchange Announcement (Translated))	U&I Corporation, a South Korean medical implant maker, announced today it will launch an IPO to raise at least KRW 37.5bn (USD 31.7m). According to a stock exchange statement to disclose the IPO prospectus, the company will offer 1.5m shares in the IPO.
4-Oct	Total Face Group mulls ASX listing - report (Source: Australian Financial Review)	Total Face Group (TFG), the Australian cosmetic clinics business, is mulling an ASX listing to raise AUD 10m (USD 7m), the Australian Financial Review's Street Talk reported. According to the report, which did not cite sources, business figure Paul Fielding has been rolling up doctor-controlled medical cosmetic outfits into a single entity over the last 18 months and is now preparing a prospectus to list the entity.
2-Oct	Watami no Kaigo to be acquired by Sampo Japan Nopponkoa Holdings for JPY 21bn (Source: Stock Exchange Announcement (Translated))	Sampo Japan Nipponkoa Holdings [TYO: 8630] announced today it will acquire Japan-based nursing care business Watami no Kaigo from Watami [TYO: 7522]. Sampo Japan will spend JPY 21bn (USD 175m) to acquire 100% of the shares in Watami no Kaigo on 1 December 2015.
2-Oct	Metro Pacific Investments mulls spinoff, IPO for hospital unit - newswire (Source: Newswire Round-up)	Metro Pacific Investments Corp. [PSE: MPI], the Philippines-listed infrastructure group, is mulling options for its hospital unit including a spin-off or an initial public offering, a newswire reported. President and Chief Executive Officer Jose Lim told Bloomberg that the company has yet to make a decision on the transaction.
2-Oct	Metro Pacific Investments looking for additional hospital acquisitions (Source: Manila Times)	Metro Pacific Investments Corporation (PSE: MPI), the Philippines-listed infrastructure group, is looking for additional hospital acquisitions, reported the Manila Times citing the president of Metro Pacific Hospital Holdings, Augusto Palisoc.
2-Oct	Legochem Biosciences to acquire 100% stake in Khanmed, instead of 20% (Source: Stock Exchange Announcement (Translated))	Legochem Biosciences (KOSDAQ:141080), a South Korean company involved in the development of new small molecule drugs, announced today, 1 October, that it has decided to absorb Khanmed, instead of the acquisition of a 20% stake. From a strategic view, Legochem has determined to take over the 100% interest in Khanmed.
2-Oct	20/20 Healthcare acquired by Konica Minolta (Source: Nihon Keizai Shimbun)	Konica Minolta [TYO: 4902], the Japan-based business technologies company, has acquired North Carolina-based medical systems company 20/20 Healthcare, the Nihon Keizai Shimbun reported. The Japanese-language report estimated, without citing sources, that Konica spent several billion JPY (several tens of millions of USD) on the deal.
2-Oct	C-Tri files application for KOSDAQ IPO; Shinhan Investment acting as manager (Source: Stock Exchange Announcement (Translated))	C-Tri, a South Korean pharmaceutical company, has filed an application for regulatory approval for a proposed IPO, according to a Korea Exchange (KRX) statement disclosed today. The company plans to float on the KOSDAQ. Dae Hwa Pharm (KOSDAQ: 067080), a listed South Korean pharmaceutical company, is the largest shareholder with a 16% stake.
2-Oct	AFT Pharmaceuticals exploring	AFT Pharmaceuticals, the New Zealand-based drug maker, is exploring various options

various options including listing (Source: The National Business Review)

including a listing, reported the National Business Review. The report cited Hartley Atkinson, the founder of AFT, who said that a listing on the Nasdaq was an option.

1-Oct	Shenzhen CAU Technology may be taken over for reverse listing - report (translated) (Source: Securities Times)	<i>Shenzhen CAU Technology (Guo Nong Ke Ji) [SZ: 000004], a China-based, listed pharmaceutical company, may be taken over for reverse listing, the Chinese-language Securities Times reported on 1 October, citing a research report by Fortune Securities.</i>
1-Oct	Tibet Rhodiola Pharmaceutical to enter into share trading halt on 8 October over significant assets restructuring planning (Source: Stock Exchange Announcement (Translated))	<i>Tibet Rhodiola Pharmaceutical [Xi Zang Yao Ye; SH: 600211], a China-based listed company, said in a stock exchange announcement today that it will enter into share trading halt on 8 October due to planning a possible significant assets restructuring.</i>
1-Oct	Metro Pacific Hospital commences tender offer to acquire remaining stake in Davao Doctors Hospital (Source: Stock Exchange Announcement(s))	<i>The subsidiary of Metro Pacific Investments Corporation (PSE:MPI), the Philippines-listed infrastructure group, plans to acquire the remaining shares in Davao Doctors Hospital, the Philippine-based hospital, via a tender offer, according to the following release: Metro Pacific Hospital Holdings, Inc.</i>
1-Oct	Watami no Kaigo to be acquired by Sompo Japan Nipponkoa Holdings for estimated JPY 21bn - report (translated) (Source: Nihon Keizai Shimbun)	<i>Sompo Japan Nipponkoa Holdings [TYO: 8630], the Japan-based insurance company, will spend an estimated JPY 21bn (USD 175m) to acquire Watami no Kaigo, the nursing care business of Japan-based restaurant chain operator Watami [TYO: 7522], the Nihon Keizai Shimbun reported.</i>

DISCLAIMER

This Information Package is distributed by Quadria Capital Investment Management ('Quadria Capital') upon the express understanding that no information herein contained is proprietary or has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any kind accepted with respect to the completeness or accuracy of any information. Also, no representation or warranty is expressed or implied is made that such information in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Information Package. Quadria Capital and its Managing Partners, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Information Package. All recipients of the Information Package should make their own independent evaluations and should conduct their own investigation and analysis and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers, as they deem necessary.

Where this Information Package summarizes the provisions of any other document, that summary should not be relied upon and the relevant documentation must be referred to for its full effect.



QUADRIA
CAPITAL

Abrar Mir
Managing Partner

Quadria Capital Investment Management Pte. Ltd.
11A Stanley Street, Singapore 068730
D +65 6805 9681 M +65 8522 1033
abrar.mir@quadriacapital.com | www.quadriacapital.com



QUADRIA
CAPITAL

Dr. Amit Varma
Managing Partner

Quadria Capital Investment Advisors Pvt. Ltd.
D-1, Clarion Collection, Shaheed Jeet Singh Marg, New Delhi – 110 016
D +91 11 4953 9901 M +91 98 1838 5665
amit.varma@quadriacapital.com | www.quadriacapital.com

This publication does not constitute an offer of, or the solicitation of, an offer to buy or subscribe for, any financial instrument or investment, nor shall it (or any part of it or the fact of its distribution) form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract or commitment whatsoever.